You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,039,728


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,039,728
Title:More potent and less toxic formulations of epinephrine and methods of medical use
Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, 1-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of 1-epinephrine, including providing prefilled syringes of pharmaceutical formulations of 1-epinephrine and methods of using these prefilled syringes by treating patients with continuous intravenous infusion instead of bolus administration.
Inventor(s): Taneja; Jugal K. (Tampa, FL)
Assignee:
Application Number:15/616,157
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,039,728
Patent Claims: 1. A method of treating a patient having, developing, or recovering from septic shock or anaphylactic shock with a continuous intravenous infusion of l-epinephrine delivered via an at least one intravenous fluid bag with an at least one intravenous line and or an at least one intravenous catheter, said at least one intravenous fluid bag containing up to 1,000 mL of a saline solution or a dextrose and sodium chloride-containing solution, said method comprising the step of injecting an at least one prefilled syringe of a 1 mg injectable liquid pharmaceutical formulation of l-epinephrine into each said at least one intravenous fluid bag or medication port thereof: said at least one prefilled syringe injectable liquid pharmaceutical formulation of l-epinephrine including a tonicity agent and having no more than 12.5% total impurities or no more than 12% d-epinephrine: said method further comprising the diluting of l-epinephrine to a concentration of about 1 microgram per mL in each said at least one said intravenous fluid bag during said continuous intravenous infusion of l-epinephrine; said method optionally comprising protecting said at least one said intravenous fluid bag from light or UV-radiation after said step of injecting said prefilled syringe into said at least one intravenous fluid bag or medication port thereof to prevent l-epinephrine degradation and impurities from forming.

2. A method of treating a patient having, developing, or recovering from septic shock or anaphylactic shock with a continuous intravenous infusion of l-epinephrine delivered via an at least one intravenous fluid bag with an at least one intravenous line and or an at least one intravenous catheter, said at least one intravenous fluid bag containing up to 1,000 mL of a saline solution or a dextrose and sodium chloride-containing solution, said method comprising the step of injecting an at least one prefilled syringe of an at least 1 mL injectable liquid pharmaceutical formulation of l-epinephrine into each said at least one intravenous fluid bag or medication port thereof; said at least one prefilled syringe injectable liquid pharmaceutical formulation of l-epinephrine including a tonicity agent and having no more than 12.5% total impurities or no more than 12% l-epinephrine; said method further comprising the diluting of l-epinephrine to a concentration of about 1 microgram per mL in each said at least one intravenous fluid bag during said continuous intravenous infusion of l-epinephrine; said method optionally comprising protecting said at least one said intravenous fluid bag from light or UV-radiation after said step of injecting said prefilled syringe into said at least one intravenous fluid bag or medication port thereof to prevent l-epinephrine degradation and impurities from forming so that said continuous intravenous infusion of l-epinephrine has a ratio of 1-epinehrine:d-epinephrine greater than 4:1.

3. A method of treating a patient having, developing, or recovering from septic shock or anaphylactic shock with a continuous intravenous infusion of l-epinephrine delivered via an at least one intravenous fluid bag with an at least one intravenous line and or an at least one intravenous catheter, said at least one intravenous fluid bag containing up to 1,000 mL of a saline solution or a dextrose and sodium chloride-containing solution, said method comprising the step of injecting an at least one prefilled syringe of a 1 mL injectable liquid pharmaceutical formulation of l-epinephrine into each said at least one intravenous fluid bag or medication port thereof; thereof: said at least one prefilled syringe injectable liquid pharmaceutical formulation of l-epinephrine including a tonicity agent and having no more than 12.5% total impurities or no more than 12% d-epinephrine; said method further comprising the diluting of l-epinephrine epinephrine to a concentration of about 1 microgram per mL in each said at least one intravenous fluid bag during said continuous intravenous infusion of l-epinephrine; said method optionally comprising protecting said at least one said intravenous fluid bag from light or UV-radiation after said step of injecting said prefilled syringe into said at least one intravenous fluid bag or medication port thereof to prevent 1-epinephrine degradation and impurities from forming so that said continuous intravenous infusion of l-epinephrine having has a ratio of l-epinephrine:d-epinephrine greater than 4:1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.